(Q39531941)

12 September 2017

Pharmacokinetic impact of SLCO1A2 polymorphisms on imatinib disposition in patients with chronic myeloid leukemia (English)

1 reference

12 September 2017

chronic myeloid leukemia

0 references

1 reference

1 reference

1 reference

Y Yamakawa

1

1 reference

12 September 2017

A Hamada

2

1 reference

12 September 2017

T Shuto

3

1 reference

12 September 2017

M Yuki

4

1 reference

12 September 2017

T Uchida

5

1 reference

12 September 2017

H Kai

6

1 reference

12 September 2017

T Kawaguchi

7

1 reference

12 September 2017

H Saito

8

1 reference

12 September 2017

language of work or name

English

0 references

publication date

1 June 2011

1 reference

Clinical Pharmacology & Therapeutics

12 September 2017

1 reference

12 September 2017

90

1 reference

12 September 2017

157-163

1 reference

12 September 2017

1

1 reference

The superfamily of organic anion transporting polypeptides

12 September 2017

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.102

Pharmacogenomics of human OATP transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.102

Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.102

Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.102

Pharmacogenetics of the organic anion transporting polypeptide 1A2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.102

Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.102

Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.102

Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.102

HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.102

Clinical pharmacokinetics of imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.102

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.102

Active transport of imatinib into and out of cells: implications for drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.102

Interaction of imatinib with human organic ion carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.102

Inhibition of imatinib transport by uremic toxins during renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.102

Variation of flavonoids and furanocoumarins in grapefruit juices: a potential source of variability in grapefruit juice-drug interaction studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.102

Intestinal drug transporter expression and the impact of grapefruit juice in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.102

Dehydroepiandrosterone sulfate (DHEAS): identification of a carrier protein in human liver and brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.102

Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.102

Catalog of 258 single-nucleotide polymorphisms (SNPs) in genes encoding three organic anion transporters, three organic anion-transporting polypeptides, and three NADH:ubiquinone oxidoreductase flavoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.102

Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.102

Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.102

Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.102

Intestinal absorption of HMG-CoA reductase inhibitor pravastatin mediated by organic anion transporting polypeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.102

Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.102

Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.102

Interaction of imatinib mesilate with human P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.102

Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.102

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.102

7 January 2021

Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.102

7 January 2021

Regional distribution of solute carrier mRNA expression along the human intestinal tract

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.102

7 January 2021

OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.102

7 January 2021

Imatinib Disposition and ABCB1 (MDR1, P-Glycoprotein) Genotype

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.102

7 January 2021

Identifiers

DOI

10.1038/CLPT.2011.102

1 reference

12 September 2017

1 reference